Lessons From the Withdrawal of Atezolizumab in Metastatic TNBC
The IMpassion130 initially paved the way for an accelerated approval—showing a clear benefit when atezolizumab was paired with nab-paclitaxel—.
This CancerNetwork news article discusses the divergent outcomes of the phase‑III IMpassion130 and IMpassion131 trials that led to the voluntary withdrawal of the FDA indication for atezolizumab (Tecentriq) in metastatic triple‑negative breast cancer. It reviews the implications of the accelerated approval pathway, highlights the importance of confirmatory trials, and examines how chemotherapy backbone differences, steroid premedication, and trial design factors may have contributed to the discrepant results.
The different outcomes of IMpassion130 and IMpassion131 illustrate the risk of over‑reliance on accelerated approvals without confirmatory evidence, and underscore the need to understand how chemotherapy regimens and supportive care practices interact with immune‑checkpoint inhibitors.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management